XRX-001: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 60 healthy volunteers ages 18-49 showed that 2 intramuscular injections of XRX-001 containing either 0.48 or 4.8 µg of antige...